Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of irinotecan liposomes (II) with famitinib or platinum chemotherapy after first-line immunotherapy progression in extensive-stage small cell lung cancer
ChiCTR2400083693Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan liposome and famitinib in small cell lung cancer (SCLC) (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
irinotecan liposomefamitinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400083693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083693.